Trials / Completed
CompletedNCT02966782
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | venetoclax | Tablet |
| DRUG | azacitidine | Powder for injection, subcutaneously or intravenous |
Timeline
- Start date
- 2017-03-07
- Primary completion
- 2023-04-05
- Completion
- 2023-04-05
- First posted
- 2016-11-17
- Last updated
- 2023-05-09
Locations
23 sites across 3 countries: United States, Australia, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02966782. Inclusion in this directory is not an endorsement.